Characteristics of patients who underwent PB NGS testing and a hematologic work-up for cytopenia(s) (n = 276)
| . | Entire cohort . | Pathogenic mutation present . | Pathogenic mutation absent . | P . |
|---|---|---|---|---|
| Patients, n | 276 | 77 | 199 | |
| Sex, n (M/F) | 135/141 | 40/37 | 95/104 | .59 |
| Age, median y (IQR) | 66 (53-73) | 71 (67-79) | 61 (49-71) | <.0001 |
| Hemoglobin, median g/dL (IQR) | 11.8 (10-13.2) | 11.2 (9.5-12.5) | 12.3 (10.3-13.3) | .006 |
| White blood cells, median K/µL (IQR) | 4.74 (3.34-6.54) | 4.91 (3.59-7.2) | 4.72 (3.29-6.3) | .061 |
| Absolute neutrophil count, median K/µL (IQR) | 2.78 (1.74-4.23) | 2.9 (1.65-4.38) | 2.76 (1.79-4.17) | .17 |
| Platelets, median K/µL (IQR) | 149 (98-224) | 141 (88-217) | 155 (99-226) | .85 |
| Abnormal CBC finding at initial visit, n (%) | ||||
| Anemia | 178 (64) | 60 (86) | 118 (59) | .0048 |
| Leukopenia | 106 (38) | 29 (38) | 77 (39) | .89 |
| Thrombocytopenia | 131 (47) | 41 (53) | 90 (45) | .28 |
| Number of cytopenias, n (%) | ||||
| 1 | 169 (61) | 39 (51) | 130 (65) | .028 |
| 2 | 75 (27) | 23 (30) | 52 (26) | .55 |
| 3 | 32 (12) | 15 (19) | 17 (8.5) | .019 |
| Cytopenia(s) defined as absolute neutrophil count <1.8 × 103/µL, hemoglobin <10.0 g/dL, platelet count < 100 × 103/µL, n (%) | 163 (59) | 52 (67) | 111 (56) | .48 |
| Bone marrow biopsy at initial evaluation, n (%) | 72 (26) | 33 (43) | 39 (20) | .0002 |
| . | Entire cohort . | Pathogenic mutation present . | Pathogenic mutation absent . | P . |
|---|---|---|---|---|
| Patients, n | 276 | 77 | 199 | |
| Sex, n (M/F) | 135/141 | 40/37 | 95/104 | .59 |
| Age, median y (IQR) | 66 (53-73) | 71 (67-79) | 61 (49-71) | <.0001 |
| Hemoglobin, median g/dL (IQR) | 11.8 (10-13.2) | 11.2 (9.5-12.5) | 12.3 (10.3-13.3) | .006 |
| White blood cells, median K/µL (IQR) | 4.74 (3.34-6.54) | 4.91 (3.59-7.2) | 4.72 (3.29-6.3) | .061 |
| Absolute neutrophil count, median K/µL (IQR) | 2.78 (1.74-4.23) | 2.9 (1.65-4.38) | 2.76 (1.79-4.17) | .17 |
| Platelets, median K/µL (IQR) | 149 (98-224) | 141 (88-217) | 155 (99-226) | .85 |
| Abnormal CBC finding at initial visit, n (%) | ||||
| Anemia | 178 (64) | 60 (86) | 118 (59) | .0048 |
| Leukopenia | 106 (38) | 29 (38) | 77 (39) | .89 |
| Thrombocytopenia | 131 (47) | 41 (53) | 90 (45) | .28 |
| Number of cytopenias, n (%) | ||||
| 1 | 169 (61) | 39 (51) | 130 (65) | .028 |
| 2 | 75 (27) | 23 (30) | 52 (26) | .55 |
| 3 | 32 (12) | 15 (19) | 17 (8.5) | .019 |
| Cytopenia(s) defined as absolute neutrophil count <1.8 × 103/µL, hemoglobin <10.0 g/dL, platelet count < 100 × 103/µL, n (%) | 163 (59) | 52 (67) | 111 (56) | .48 |
| Bone marrow biopsy at initial evaluation, n (%) | 72 (26) | 33 (43) | 39 (20) | .0002 |
Data are shown for entire cohort and are also stratified by the presence or absence of a pathogenic mutation in PB. P values were calculated using the unpaired Student t test (with or without Welch’s correction) for continuous variables or Fisher’s exact test for nominal variables. Bold indicates statistical significance. Cytopenia(s) was defined as absolute neutrophil count, <1.8 × 103/µL; hemoglobin, <10.0 g/dL; and platelet count, < 100 × 103/µL.11 Time frame for bone marrow biopsy at initial evaluation was <6 mo with no clinical intervention.
CBC, complete blood count; IQR, interquartile range.